MENU
+Compare
HELX
ETF ticker: BATS
AS OF
Feb 21 closing price
Price
$30.08
Change
-$0.55 (-1.80%)
Net Assets
12.24M

HELX stock forecast, quote, news & analysis

Category: @Health
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for HELX with price predictions
Feb 13, 2025

HELX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on February 10, 2025

HELX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 45 cases where HELX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

HELX moved above its 50-day moving average on February 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HELX crossed bullishly above the 50-day moving average on January 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 350 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 279 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HELX as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HELX turned negative on February 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HELX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 41.27B. The market cap for tickers in the group ranges from 214.5M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is FDMT at 214.5M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 23%. For the same ETF, the average monthly price growth was 29%, and the average quarterly price growth was 98%. NTLA experienced the highest price growth at 27%, while SLP experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was 6%. For the same stocks of the ETF, the average monthly volume growth was 27% and the average quarterly volume growth was 125%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 69
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 70
Seasonality Score: -61 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com